Attributes | Values |
---|
rdf:type
| |
Description
| - Monoclonal antibodies have dramatically changed the treatment possibilities for follicular lymphoma. 90Y-ibritumomab tiuxetan (Zevalin?) is the first radioimmunotherapy agent approved for the treatment of relapsed and resistant follicular lymphoma patients. Long-term benefi t was observed especially for patients achieving CR after radioimmunotherapy.
- Monoclonal antibodies have dramatically changed the treatment possibilities for follicular lymphoma. 90Y-ibritumomab tiuxetan (Zevalin?) is the first radioimmunotherapy agent approved for the treatment of relapsed and resistant follicular lymphoma patients. Long-term benefi t was observed especially for patients achieving CR after radioimmunotherapy. (en)
- Monoklonální protilátky dramaticky změnily možnosti léčby folikulárního lymfomu. 90Y-ibritumomab tiuxetan (Zevalin?) je první radioimunologický prostředek schválený pro léčbu pacientů s recidivujícím a rezistentním folikulárním lymfomem. (cs)
|
Title
| - Relapsed follicular lymphoma sequentially treated with ritusimab and 90-Y-ibritumomab tiuxetan
- Relapsed follicular lymphoma sequentially treated with ritusimab and 90-Y-ibritumomab tiuxetan (en)
- Recidivující folikulární lymfom následně léčený ritusimabem a 90-Y-ibritumomab tiuxetanem. (cs)
|
skos:prefLabel
| - Relapsed follicular lymphoma sequentially treated with ritusimab and 90-Y-ibritumomab tiuxetan
- Relapsed follicular lymphoma sequentially treated with ritusimab and 90-Y-ibritumomab tiuxetan (en)
- Recidivující folikulární lymfom následně léčený ritusimabem a 90-Y-ibritumomab tiuxetanem. (cs)
|
skos:notation
| - RIV/61989592:15110/07:00004014!RIV08-MZ0-15110___
|
http://linked.open.../vavai/riv/strany
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| - P(NR9502), Z(MSM6198959205)
|
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15110/07:00004014
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - Follicular lymphoma; Ibritumomab tiuxetan; Rituximab; CD20 antigen; Therapy; Positron emission tomography (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Indrák, Karel
- Kubová, Zuzana
- Raida, Luděk
- Procházka, Vít
- Kučerová, Ladislava
- Papajík, Tomáš
- Buriánková, Eva
- Mysliveček, Miroslav
- Drymlová, Jaroslava
|
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |
http://localhost/t...ganizacniJednotka
| |
is http://linked.open...avai/riv/vysledek
of | |